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Abstract

The number of individuals being tested for hereditary cancer syndromes has greatly
increased in the last several years and many people receive Variants of Uncertain Significance
(VUS) as a test result. Although VUS results should not guide medical management, patients and
even some healthcare providers continue to use a VUS to alter or receive unnecessary medical
care.
We conducted a needs assessment via literature review and analyzed VUS patient
interviews from a previous study with the goal of identifying various themes that could help
determine content, layout, and messaging to incorporate into online educational materials. The
needs assessment found few educational materials and identified the following themes: people
may take inappropriate medical actions based on VUS results, people report feeling confused
regarding their VUS result and how it is not helpful in determining medical management, rates of
family sharing regarding genetic test results and family history of cancer remain low, people
express concerns about sharing family history information, and advice from patients with a VUS
regarding how to share test results and cancer risk information and why it is important.
Using findings from the needs assessment we developed materials to educate patients
about their VUS result, provide information about risks associated with a family history of
cancer and prompt them to share cancer risk information with family members to promote cancer
screening and prevention. Materials were evaluated using the CDC Clear Communication Index
Score Sheet. This identified two areas in which to improve, including the number of main
messages and numeracy. However, we determined that rather than one single main message we
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were comfortable with the materials reinforcing three main messages. Finally, we describe our
ongoing process of collecting feedback from patients and healthcare providers that will be used
to modify the materials before they are tested as part of a formal research study.

iv

Introduction

Around 2-5% of all colorectal cancers and 5-10% of breast cancers are caused by a
hereditary cancer predisposition syndrome, such as Lynch Syndrome or Hereditary Breast and
Ovarian Cancer Syndrome (Sehgal et al., 2014; Apostolou & Florentia, 2019). Increases in
testing availability and the number of genes tested has led to many people being identified as
having a Variant of Uncertain Significance (VUS), where it is uncertain whether the gene change
increases cancer risk or not. Based on the American College of Medical Genetics (ACMG)
recommendations, a VUS should not change a patient’s medical management, and it is pertinent
that they understand this so they do not receive unnecessary medical interventions (Richards et
al., 2015).
Risk appropriate care is complicated in patients with a VUS because current professional
guidelines, such as the National Comprehensive Cancer Network, may call for increased cancer
surveillance or medical interventions based on their family history rather than their genetic test
results, as VUS results alone are insufficient to warrant medical interventions or increased
surveillance. Women with a first-degree family member who has had breast cancer are at double
the baseline risk for developing cancer themselves, putting their lifetime risk at around 24%
(Brewer et al., 2017). Individuals who have one or more close family members with colorectal
cancer are at two to eight times the risk of developing colon cancer themselves (Butterworth,
Higgins, & Pharoah, 2006), which can increase these individuals’ risk to around 10%.
The National Comprehensive Cancer Network Guidelines [NCCN] for Breast Cancer
Screening and Diagnosis (2020a) state that women with a computer-modeled risk of over 20%
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(based on family history) may consider receiving a yearly mammogram as early as 30-years-old,
and a yearly breast MRI as early as 25-years-old. These ages are significantly younger than the
recommendation for women with an average risk, who should begin receiving mammograms
yearly at around age 40 (NCCN, 2020a). The NCCN guidelines for Colorectal Cancer Screening
(2020b) state that individuals with a first-degree relative with colorectal cancer or high-grade
polyp at any age may receive a colonoscopy at 40, or 10 years before the earliest diagnosis in the
family. Again, this is significantly younger than the recommendation for people with an average
risk, who should begin colonoscopies at around age 50 (NCCN, 2020b).
Family sharing of familial cancer risk information is low, limiting the ability to reduce
cancer related morbidity and mortality among relatives who are at higher risk than the general
population (Bowen et al., 2017; Kinney et al., 2014; Eizjenga et al., 2018; Wiseman et al., 2010;
Chivers, et al., 2010). Communication about both VUS results and family cancer history appear
to be subpar and there is little patient-friendly educational material that addresses both of these
topics (Bowen et al., 2017; Kinney et al., 2014; Eizjenga et al., 2018; Wiseman et al., 2010;
Chivers, et al., 2010). Our study aims to create and evaluate material that will directly address
the needs of this patient population.
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Overview of Process
Prior to developing an educational tool, we conducted a needs assessment that included a
literature review and analysis of VUS patient interview transcripts. Findings from this review
and analysis were organized into a table by themes and used by the evaluation team to create
educational materials. The first author, MK, evaluated materials using the CDC Clear
communications index score sheet to assess the clarity and understandability of the educational
materials. The evaluation plan was reviewed by the University of South Florida’s Institutional
Review Board (IRB) and determined to be exempt from IRB oversight as it consisted of an
iterative evaluation designed to gain feedback about the educational materials from both patients
who had received a VUS result and genetic healthcare providers.

Needs Assessment
The needs assessment began with a literature review using the search terms, “Variant of
Uncertain Significance,” and, “Variant of Uncertain Significance education.” in the University of
South Florida’s online, “FindIt!” service that includes hundreds of databases such as Pubmed and
CINAHL. Abstracts were scanned by MK to determine relevancy to the study. Studies that
discussed patient and provider perception and understanding of VUS test results, how they
communicate (or do not communicate) such results to family members, and how patients feel
about such test results were included. Excluded were articles that did not involve genetic testing,
discussed VUSs in non-cancer genetics specialties or different testing modalities (e.g.:
microarray), and articles discussing reclassification of specific VUS test results. Ten studies
directly related to the project were identified. The major and minor findings of the studies were
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synthesized into a table by MK. When deemed useful, direct quotes were also organized into the
table. After the first few notable findings, themes from the data began to emerge and key
findings were then organized into thematic categories by MK. For example, a handful of studies
discussed how a VUS may lead individuals to undergo medical management that may not be
risk-appropriate. These findings were grouped together under the theme “Taking inappropriate
action based on a VUS result.”
Interview transcripts from a previous study involving six women with VUSs in a cancer
risk gene were each reviewed by the first author, MK. This was done to increase familiarity with
the content of the interviews and provide a general understanding of the topics addressed in the
interviews, which included feelings regarding VUS results and family sharing of results. MK
then completed a second review to systematically extract any information that supported or
added new content to the themes from literature review, and to identify additional themes and
content that might help inform the development of educational materials.
To complete this process, interviews were read segment by segment with each segment
being compared to the literature review data table to determine if it added detail to an existing
theme or belonged to a novel theme. For example, quotes from transcripts were added to
illustrate the theme from the literature review regarding confusion over what a VUS is.
A few new themes were added to the table to represent other findings extracted from
transcript sections. These included descriptions of various feelings about the uncertainty
surrounding their VUS results, attitudes surrounding the importance of sharing information, and
advice to other VUS patients. For each of these unique themes, exemplary quotes were extracted
and added to the table to represent the range of responses from the six patient interviews.
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Upon completion, the table was shared and reviewed by DC, a member of the evaluation
team who has experience in qualitative data analysis and thematic categorization. The themes
and supporting examples were discussed, revised, and recategorized until agreement was reached
and thematic categories were finalized.

Needs Assessment Findings
The initial literature review found evidence that many patients struggle to understand
their VUS result and have a hard time accepting the lack of medical management that comes
with it (Bowen et al., 2017; Kinney et al., 2014; Eizjenga et al., 2018; Wiseman et al., 2010;
Chivers, et al., 2010). Further, there is evidence that non-genetics providers are often tasked with
interpreting these results, which increases the rate of inappropriate medical management, such as
prophylactic mastectomy when it is not indicated (Murray et al., 2011; Macklin et al., 2019).
Patients tend to misinterpret their own results, and subsequently may communicate inappropriate
or less reassuring messages to family members (Reuter et al., 2019; Medendorp et al., 2020). The
less reassuring and clear the patient was in explaining the result to family members, the more
likely the family member was to perceive cancer as hereditary as well as higher cancer risks (Vos
et al., 2011). Table 1 summarizes key findings of the literature review and analysis of interview
data. No research studies were identified that detailed the development of educational tools for
VUS patients. One study mentioned an online tool developed to help family members of a VUS
patient understand the result in the context of family variant interpretation research studies
(Garrett et al., 2016). While some elements of this website are similar to ours, including a
description of VUS results and how to contact family members to explain such results, overall, it
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is not an interactive tool designed to increase family sharing of cancer risk information for
personal cancer risk reduction (Garrett et al., 2016).
A review of VUS patient interview transcripts further supported the literature review
findings. Some patients expressed initial confusion over their results, which then turned into
frustration due to the lack of meaning these results have for medical management. Other patients
seemed to understand that although the results won’t change anything now, it might be important
for family members to know about a VUS in case more information is found in the future.
When prompted to offer advice to other individuals who might receive a VUS result on
genetic testing, all of the participants readily offered their insight. Advice included disseminating
risk information throughout the family in steps, starting with the family members perceived to be
the most supportive. One patient expressed that sharing VUS results should be considered a
necessity, while another patient and her husband described how they will only reveal their VUS
to their family members should it be reclassified as pathogenic. They explained that for the time
being, they shared familial risk information and should they pass away before the VUS is
reclassified, their test result is included in their will.
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Table 1
Findings from the Needs Assessment

Theme

Quotes/other Evidence

Incorporation into Educational Tool

Taking
inappropriate
medical action
based on a
VUS result

Of 22 women who had a BRCA VUS (including three likely pathogenic) and received a Risk
Reducing Oophorectomy, 20 had a personal history of breast cancer and 2 had a family history of
breast or ovarian cancer subsequently two of these women had their result reclassified as benign
and one woman had her VUS upgraded to deleterious. (Murray et al., 2011).

Messages include: 1) VUS results should not
usually change medical management; 2) Genetic
testing for the VUS is not usually helpful for family
members because it is not used to change their
medical care; 3) Medical care is usually based on
personal and family history of cancer.

Almost 60% of surveyed physicians reported they would not feel comfortable explaining VUSs to
patients (Macklin et al., 2018)
76% of providers surveyed recommended familial genetic testing for a VUS (Macklin et al., 2018).
“Previous studies have shown that patients struggle with the ambiguity of a VUS result and
confusion over its clinical implications.” (Reuter et al., 2019. p. 883).

Confusion
over what a
VUS is and
frustration
about how it is
not helpful

“… VUS reports discussed with counselees are too frequently inaccurately perceived typically
leading to overestimation of cancer risks, adverse psychological outcomes and more radical medical
decisions” (Eccles et al., 2015, p. 2062).
“Like I said, I was hoping more for a yes or a no because I was going to use these results to
determine if I felt like I needed to do any further precaution. Prophylactic treatment. That's why I
was [wanting] more of a yes or no because that was going to help me weigh my decision of what to
do next.” [Participant 1, Female, BRCA2 VUS]
[regarding initial feelings of receiving VUS result] “Really what does "variance of unknown
significance" mean? That was my biggest question that I had, that I wanted answers to ...”
[Participant 1, Female, BRCA2 VUS]
Two studies showed that between 6.6% and 15% of those with a VUS result perceived their risk of
carrying a predisposition to cancer as nonexistent. Still, other studies show that individuals with a
VUS result still perceive their risk of having a pathogenic mutation as high. Other reports show that
perceived cancer risk after a VUS result decreases with time (Medendorp et al., 2020).
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Messages explain how a VUS doesn’t change
anything at this point in time and most VUS results
are later found to be normal variation – not disease
causing.
Patient stories or quotes that offer a relatable
perspective and explanation of how others who
received a VUS result expressed some confusion
and frustration.

Table 1 (Continued)
Theme

Quotes/other Evidence

Incorporation into Educational Tool

Family members are
often not aware of the
test result. They also are
unaware how cancer
family history can
increase risk for cancer
(even when no genetic
cause is found).

Of 85 women who had a mother/sister with breast cancer and a VUS in BRCA1/2:
42% said they felt very little info was shared with them
52/81 said they believed the result was negative
22/81 were unaware of the test result
69/81 were not aware their family member had been provided a summary letter (Himes et al.,
2019).

Handouts & videos for family members that
1) Describe a VUS result simply and
accurately 2) Address that having a closely
related family member with cancer can
increase one’s lifetime risk for cancer and
may change recommendations for medical
care.

Family members reported that general print materials would be most helpful (in the context of
Lynch syndrome) (Petersen et al., 2019).
How a VUS result is communicated to other at‐risk family members influences how those
individuals perceive the result as well (Vos et al., 2011).
Many patients attributed their cancer risk to environmental or behavioral factors upon receipt of
a VUS result, completely ruling out the possibility of any genetic etiology (Reuter et al., 2019).
Those without a strong family history of cancer were more likely to view a VUS as being
insignificant in their own cancer diagnosis (Reuter et al., 2019)

“However, patients struggled to understand that the absence of a pathogenic variant did not rule
out a genetic etiology for the cancers in their family, a theme which has been previously
documented in the context of BRCA1 and BRCA2 testing,” (Reuter et al., 2019, p. 881).
Concerns about sharing
with family members

People face difficulties when deciding whether to communicate personal health information
(Greene et al., 2012).
There are very few reports of clinicians disclosing shared cancer risk information with their
patients’ family against the patient’s wishes (Mendes et al., 2016).
“Successful family communication about important genetic information is dependent on a
number of factors including pre-existing family dynamics and an individual’s ability to give and
receive complex genetic information.” (Hodgson et al., 2014, p. 4).
One of the most powerful predictors of whether a woman will share her genetic information is
based on her perceived reaction of the family member (Montgomery et al., 2013).
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Experiences and quotes from VUS patients
discussing their concerns about family
member reactions and outcomes of
disclosing information.
Handouts for family members of VUS
patients.

Table 1 (Continued)
Theme

Quotes/other Evidence

Incorporation into Educational
Tool

Advice from
people with
VUS results
about sharing
VUS result with
family members

“I definitely think that it's a positive thing. I don't see any negatives to doing it, so why wouldn't you? At
least from my perspective anyways, I don't see a negative to it, but then again, I have a family that has
always been supportive and so I knew that they would be supportive still with this. Somebody who
doesn't have that type of family, I guess, maybe my suggestion would be to share first with somebody
who you know is going to be supportive so that you can get that reinforcement or that courage that you
need to continue to share with others.” [Participant 1, Female, BRCA2 VUS]

Experiences and quotes from VUS
patients discussing their concerns about
family member reactions and outcomes
of disclosing information.
Handouts for family members of VUS
patients.

“I would tell them that if you really love the people in your life, this is information that they need to
have. There's no decision or question in my mind about the necessity of sharing this information.”
[Participant 2, Female, BRCA2 VUS]
“We actually have a copy of the genetic testing in with our will and trust. And if we both pass at the same
time then that information will become available. We have four children, we have 12 grandchildren. But
we chose to not share it [VUS] with them unless we get an update in the future from [Cancer Center] that
says, yeah this is an important thing to share. You know?” [Participant 3, Female, BRCA2 VUS]
Importance of
sharing cancer
risk and cancer
screening
information with
family members

“Or if it's something that they would be of concern, you know, at passing on to their children or so on,
then ... You know what we've shared with them so far is, mom had severe colon cancer and therefore you
should have early testing [screening for colorectal cancer] and that your kids should know about it so that
they should probably be tested [screened for cancer]. That's just an example.” [Participant 3, Female,
BRCA2 VUS]

Language emphasizing the importance
of sharing cancer risk information so
family members can get the medical
care that is right for them – care that
may even save their life.

Desiring more
information

[Regarding having take-home educational info about her result] “My husband and I looked at it on
numerous occasions too, so I do feel like having something more than just the results to go home with,
something else that talks about genetics, et cetera, was helpful.” [Participant 1, Female, BRCA2 VUS]

Website providing them more
information including VUS handouts
and a video.
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Educational Materials Development
Educational materials were primarily developed by MK and DC with input from a PhD
researcher in Health Communication (MDK) and several other evaluation team members. We
began by building on and modifying existing educational material about VUS results that had
been created previously by several evaluation team members as part of an audio/visual tool
describing possible genetic test results. The team decided that including audio as well as visual
animations might make the content was more interactive as part of several brief videos.
When developing the materials, the team felt it was important to help patients
differentiate between sharing cancer family history information and VUS test results because a
family history of cancer has the potential to change management for family members (Richards
et al., 2015, NCCN 2020a, NCCN 2020b), and thus was deemed more important to be shared
than a VUS result that should not change medical management based on ACMG guidelines
(Richards et al., 2015). Nevertheless, we acknowledge other reasons why family members may
benefit from knowing that someone in the family had genetic testing.
Addressing family communication was also an important part of the tool. We found from
patient interviews that hearing the experiences of others who have gone through a similar
situation may be helpful. As such, advice about sharing VUS or cancer risk information was used
to develop handouts with quotes inspired by the interviewees that address concerns about sharing
family information. Further, the concern with sharing accurate information with family led to the
development of the single-page handouts that participants could easily email or print to share
accurate and simple information with their family members.
Once the overall format was established and draft materials created, many rounds of
editing by evaluation team members involved working on the level of vocabulary used and how
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information was presented in each of the different aspects of the tool with the goal of making the
materials as succinct and clear as possible. After several rounds of review and edits by the
evaluation team, one interactive video about VUS results, two videos explaining breast and colon
cancer risks and screenings, three single-page handouts, and two handouts with advice or ideas
of what one could say to family members were developed. These multiple components were
ultimately integrated into a single website. The main components are described in more detail
below.
The main resource is a three-minute, interactive video designed to explain VUS results to
patients as well as introduce the idea of familial cancer risks and that cancer could be prevented
or found early when it is easier to treat. To keep the length of the video short we included two
“learn more,” options to explain genetic testing and the reclassification process for VUS results
in more detail.
The website included frequently asked questions (FAQs), which succinctly answer
several questions people with a VUS might have such as, “What is a VUS?”, “Should my family
members be tested for the VUS?”, and “What information should I share with my family
members?” Together the VUS educational video, FAQs, and single page VUS handout describe
VUS results, explain that VUS results should not be used to change medical management,
discuss familial risks associated with cancers regardless of genetic testing, and link to support
materials that can be printed and aid in discussing risks with family members.
Two additional videos (about two minutes each) were produced to explain how a family
history of colorectal cancer or breast cancer affect lifetime risks for developing those cancers and
the efficacy of cancer screening. Two single-page handouts reinforced the content in the
educational videos, explaining how a family history of colorectal or breast cancer can affect
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lifetime risks for cancer and prompting individuals with a family history to talk to their
healthcare providers about cancer screening.

Evaluation Methods using the Clear Communication Index
The Centers for Disease Control (CDC) Clear Communication Index Score Sheet (2020) was
used to evaluate the educational materials after incorporating feedback or improvements
provided by several research team members. This Index Score was designed to assess
educational or other communication materials’ main messages, language levels, information
design, and behavioral recommendations, among other measures (CDC, 2020). The index score
is created based on multiple criteria such as, “Does this material contain one main message
statement?”, and “Is the main message at the top, beginning, or front of the material?” For
questions in which the education materials meet the outlined criteria, a score of 1 is given. A
score of 0 is given if it does not meet the criteria. Scores of 90 and above are considered passing,
while those that fall below do not pass.

Evaluation Findings using the Clear Communication Index
Using the CDC Clear communications Index Score Sheet, the educational materials as a
whole scored 60 out of 100. Reasons for point deductions include the materials having three
main messages as opposed to a single main message, as well as the use of passive voice in the
call to action portion of the educational materials. Further, while the materials did define and
explain a number of terms, points were lost because not all unfamiliar terms are explained or
described, instead being simply defined. In the breast and colon cancer risk videos, the words
such as mammogram and colonoscopy are defined but not explained in detail.
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In terms of numeracy, the materials also lost points as they do not always explain what
numbers mean. For example, lifetime risks for cancer in various scenarios are presented to
patients as a percentage (e.g. women in general have a 12% lifetime risk of developing cancer)
but these risk figures are not defined or explained in another way.
Areas in which the materials excelled include having at least one call to action (in this
case sharing cancer risk and screening information with family), using numbers that are familiar
to the audience such as whole numbers when describing the efficacy of mammograms and
colonoscopy (rather than percentages or fractions), and explaining how having a family history
of cancer can increase cancer risks to the audience. The materials earned additional points
because the benefits and risk associated with the recommended behavior (e.g. family cancer risk
information sharing) were acknowledged.

Evaluation of Materials by Patients and Providers
To further improve the educational materials, we planned to elicit feedback from cancer
genetic healthcare providers as well as patients with a VUS in an iterative manner until
saturation of feedback is reached. This plan involves offering participants a short pre-survey after
which they review the materials and then complete the post-survey. A subset of individuals will
be asked to participate in interviews designed to gather additional feedback on the materials.

Survey Measures
The Disclosure Decision Making model and the COM-B behavior change model were
used to develop patient and provider surveys (Greene et al., 2012; Michie et al., 2011). The
Disclosure-Decision Making Model states that constructs such as anticipated response of family
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members and disclosure efficacy (e.g.: a person’s perceived ability to accurately relay such
information to others), and the relationship quality between two individuals determine whether a
person will disclose health information to family members (Greene et al., 2012; Michie et al.,
2011). To assess the first two constructs, VUS participants were asked if they agreed or
disagreed with statements such as, “I believe sharing cancer risk information will upset some of
my family members,” and, “If I wanted to share this information, I am confident I would be able
to explain the information.” These questions were assessed in the patient pre- and post-surveys to
see if the material influenced these constructs. Questions assessing relationship quality between
them and their first-degree family members were included in the initial draft of the survey but
were subsequently removed for the sake of brevity.
The COM-B model states that behavior change (i.e., familial cancer risk disclosure) is
related to an individual’s perceived capability, opportunity, and motivation (Michie et al., 2011).
Motivation was assessed using twenty-five 5-point Likert-type questions asking the extent to
which they agree or disagree with statements such as, “Sharing information with all my adult
family members is something I want to do.” Opportunity was assessed with eighteen 5-point
Likert-type statements such as, “If I decided to share this information with all my adult family
members, I would have the chance to do it.” Capability was assessed with eight 5-point Likerttype statements such as, “I am confident I would know what to tell my family members.”, and, “I
am confident I would be able to deal with their reactions.”
While this study lacked the statistical power to evaluate the efficacy of the material,
knowledge questions were included in the pre- and post-surveys for VUS participants to assess
changes in knowledge. Examples of knowledge questions included, “Finding a VUS usually
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means someone should get cancer screening more often than those without a VUS,” and, “When
a person has cancer, their family members may be at higher risk for cancer.”
Participants were asked for basic demographics including their age group, if they had
ever been diagnosed with cancer (which cancers and at what age) as well if any of their family
members had been diagnosed with cancer (which cancers).
Both provider and patient participants were asked questions regarding their perceived
acceptability and appropriateness of the materials. These questions were based on existing fouritem measures known as Acceptability of Intervention Measure (AIM) and Intervention
Appropriateness Measure (IAM) (Weiner et al., 2017). These measures include Likert-type
statements such as, “I like the educational materials,” and, “the educational tools meet my
approval.” All participants were also provided free response questions in the post-survey
requesting their feedback regarding the materials.
As part of the pre-survey, providers were asked basic demographics questions such as
their gender, how long they have been involved in Cancer Genetic Counseling, and how much
time they spend counseling patients about VUS results. They were also asked six 5-point Likerttype questions asking the extent to which they agree with statements such as, “I encourage
patients with a VUS to disclose their test results to family members.”, and, “ For patients with
breast or colorectal cancer who don’t have a pathogenic variant, I usually talk to them about
increased cancer risks for their first degree relatives.”

Semi-structured interview guide
Semi-structured interviews were planned for those participants who expressed
willingness to be interviewed on the survey. These interview questions aimed to expand on the
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participants’ specific answers to survey questions and gather more detailed feedback about the
educational materials.

Sample Recruitment and Procedures
Patients 18 years and older with a personal or family history of breast or colorectal
cancer and a VUS result on genetic testing were recruited from the Inherited Cancer Registry
(ICARE) via email invitations. Healthcare providers were recruited by the National Society of
Genetic Counselors (NSGC) website directory. Providers who indicated they practiced in Cancer
Genetics and were open to student contact were emailed. Emails were sent out in multiple
rounds, with ten emails sent per batch. If an insufficient number of participants responded after
five days, the next batch of ten emails was sent.
Participants were able to access an informational document that described the evaluation
procedures including the voluntary nature of the evaluation, time involved, and how they would
be compensated $15 for completing the pre-survey, reviewing the materials, and completing the
post-survey. They were instructed to proceed to the pre-survey if they chose. After completing
the pre-survey they were linked to the online, educational material and were instructed to follow
a link to the post-survey after reviewing the materials. Once participants finished the post-survey
they were invited to sign up for a semi-structured interview.
For future data collection, participants who agreed to an interview as part of the initial
survey will be contacted for interview via online video chat such as Microsoft Teams or Zoom.
Each interview should last about 30-45 minutes where participants will be asked follow-up
questions about the acceptability and understandability of the material as well as ways to
improve it. Individuals who complete interviews will be given another fifteen dollar gift card.

16

Findings from Patient and Provider Surveys and Interviews
At the time of write up, recruitment of provider and patient participants had begun, but no
complete responses had been collected from the surveys and thus no interviews had been
conducted.
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Discussion
After conducting a needs assessment, we developed educational materials designed to
address patient understanding of VUS results as well as risks of family cancer history and
benefits of cancer screening to fill a gap we identified. Although one website,
FindMyVariant.org, was identified through literature review its purpose was to find family
members of those with a VUS for familial segregation analysis in hopes of resolving VUS results
more quickly (Garret et al., 2016). While FindMyVariant addresses family communication, its
main purpose is related to collecting data for VUS reanalysis rather than for the purpose of
cancer screening and management in other at-risk family members based on cancer family
history (Garrett et al., 2016).
FindMyVariant does not address that it is important for family members to know cancer
family history information because it may alter their own cancer screening and risk management
options (Garrett et al., 2016). Further, the FindMyVariant website actively promotes the sharing
of VUS results, while our materials attempt to let the patients decide whether to share their VUS
result, while emphasizing the importance of sharing family cancer history. FindMyVariant
describes how they can use various tools such as social media and other mutual contacts to reach
out to more distant family members rather than addressing concerns patients might have about
family communication (Garret et al., 2016). Finally, the FindMyVariant website consists of
online text, but does not have videos or printable/downloadable handouts.
For many individuals, the idea of obtaining a VUS result on genetic testing, or a familial
risk for cancer can seem nebulous. Around half of adults in the US have intermediate health
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literacy, meaning they possess some skills that are deemed necessary to perform moderately
challenging literacy activities, but this does not include the ability to find the definitions of
medical terms they may come across on their own (Kutner et al., 2006). This was considered
heavily when developing the tool. However, the materials lost points in the numeracy section of
the Clear Communication Index Score Sheet. The example in the CDC index says, “The amount
of meat recommended as part of a healthy meal is 3 to 4 ounces – it will look about the same as a
deck of cards” (2020). There is difficulty in further quantifying lifetime risks for cancer, other
than percentages. They could be expressed in two different ways by saying, “Having one firstdegree family member with colorectal cancer doubles the risk for cancer.” However, this may be
misleading because a doubled risk could be as low as 10% given general population risks for
colorectal cancer. An alternative we will consider is to say 1 in 10 individuals who have a close
family member with colorectal cancer will also get colorectal cancer in their lifetime. We will
assess the presentation of cancer risks and alternative presentations when receiving feedback
from patients in order to gain a better understanding of how they perceive those numbers.
Based on criteria from the Clear Communication Index Score Sheet, educational
materials should have a single main message (2020). Given the complex nature of VUS genetic
test results and familial cancer risks, distilling the message down to one point is nearly
impossible. Notably, if the Clear Communication Index Score Sheet were modified to allow up
to three main messages, scoring of the educational materials improves from 60% to 80%, where
each point is worth 5% of the total score. The first question, worth one point, is if the material
has one main message. If the answer to this is, “no,” then points are lost for this question and
automatically lost for the next three questions which assess if the main message is at the top of
the materials, if the main message is emphasized with visual cues, and if there is at least one

19

visual that conveys the main message. If three main messages were allowed, the material gains
points for all of these items. The main messages are emphasized with visual cues, (they are
animated to appear with the narration and are encapsulated in boxes that match the theme of the
materials) as well as portrayed with a visual. In addition, there are many visuals in the each
component of the material that support the main messages. For example, a visual representation
of the proportion of people who will survive if cancer is found at an early stage compared to a
later stage is included in both the breast and colon cancer videos.
In order to get the materials an additional ten points for a passing grade of 90, it would
require two more items be changed to fit the criteria in the score sheet (2020). Two items that
could be changed relate back to literacy and numeracy. For example, if every unfamiliar term
were explained rather than simply defined, the materials would gain a point, or five percentage
points. As stated previously, if every number used were explained in simple language, it would
gain another point, or five percentage points. Still, these changes would only promote the
materials to a passing grade if three main messages were allowed.

Practical Implications
In general, doing a need assessments via literature review is a helpful way to guide
development of educational materials in hopes they better meet the needs of the target
population. For this particular study, the, “corporate approach,” was taken (Stevens & Gillam,
1998). This approach is described as a method in which informants (which include physicians,
public health officials, patients, and other allied health professionals), provide knowledge and
guidance as to what patient needs are (Stevens and Gillam, 1998). Thus, a needs assessment is
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the first step to developing educational materials that will be deemed acceptable and efficacious
by patients.
Another important step in developing educational materials includes review by experts in
the field (Arora, Sinha, Malhotra, & Ranjan, 2017). In fact, it is recommend this step is
completed before patients are provided with the material (Arora et al., 2017). A focus group has
been planned with various cancer genetics experts involved with the research team in order to
further edit the materials before patients are asked to review the materials.
Once feedback from providers and patients is received and the materials completed,
testing the materials in a clinical setting with genetic counselors or other genetics providers may
also help assess its acceptability. This is particularly important because acceptability as assessed
by providers can determine whether or not providers will implement the tool in their own
practice and whether patients will follow the recommended behavioral change (Sekhon,
Cartwright, & Francis, 2017).

Limitations
Limitations of this needs assessment and evaluation include a low level of patient and
provider participant recruitment at the time of write-up. To address this, it was decided that
participants be directly invited to review the tool via interview, rather than complete a two-part
survey.
Only one member of the research team conducted the literature review and systematically
analyzed the interviews. However, a second evaluation team member had reviewed the
transcripts previously and helped with thematic categorization of findings. Additionally,
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reliability of the CDC Clear Communication Index Score could be determined if the materials
are independently scored by multiple individuals.

Conclusion
To our knowledge, this is the first time VUS educational materials have been developed
in a systematic way, focusing on previous research to address the concerns and unique needs of
VUS patients. The novel educational materials were designed to aid VUS patients in
understanding their genetic test result, the importance of sharing familial cancer risks, and assist
in family communication of cancer risk (and VUS results if they choose). While the iterative
feedback process from patient and provider participants is not yet complete, future aims include
receiving such feedback and adjusting the materials accordingly. After this evaluation process is
complete, studies on the efficacy of the material may commence.
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